A leader in the pharmaceutical industry, AstraZeneca has always been committed to promoting "patient-centered" innovation. The new campus will help serve this goal and support AstraZeneca's transition from a traditional manufacturer of medicine to an innovative healthcare company, said Wang Lei, CEO of AstraZeneca China.

Wang added that Wuxi is at the forefront of AstraZeneca's effort to advance cross-border cooperation and create an innovation ecosystem.

Innovative companies from China and other countries, including Russia, the United Kingdom, and Sweden, have agreed to set up operations in the campus.